Seoul Pharma Co., Ltd (KOSDAQ:018680)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,956.00
0.00 (0.00%)
At close: Sep 11, 2026

Seoul Pharma Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
1,739753.641,6993,517855.09-9,689
Depreciation & Amortization
2,6622,6622,4901,9282,6132,528
Loss (Gain) From Sale of Assets
1.91.780.058.260.020.01
Asset Writedown & Restructuring Costs
----2,177198.8
Loss (Gain) From Sale of Investments
---67.49-63.71--
Provision & Write-off of Bad Debts
41.5824.64-14.53-6.14-9.6424.12
Other Operating Activities
111.14944.031,5492,270-207.944,898
Change in Accounts Receivable
3,077631.55-4,071-111.42-381.62-1,261
Change in Inventory
2,545523.9-1,623-1,920-2,769270.5
Change in Accounts Payable
-171.97-469.53-410.48-164.121,0201,173
Change in Other Net Operating Assets
-400.84-3,186-2,559-193.42-3,375181.78
Operating Cash Flow
9,7711,886-3,0085,265-78.21-1,675
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-843.01-861.26-2,229-1,893-1,233-1,157
Sale (Purchase) of Intangibles
-32.72-32.46-0.7-1.52-66.23-10.71
Investment in Securities
--3,146-4,023-3.18
Other Investing Activities
55.550.75540.7455-331
Investing Cash Flow
-820.23-842.971,457-5,862-1,332-1,099

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-2,0003,000-4,0004,000
Long-Term Debt Issued
--10,000--10,000
Total Debt Issued
-2,00013,000-4,00014,000
Short-Term Debt Repaid
----4,000-4,000-2,000
Long-Term Debt Repaid
--672.39-10,620-465.7-474.25-10,465
Total Debt Repaid
-2,676-672.39-10,620-4,466-4,474-12,465
Net Debt Issued (Repaid)
-2,6761,3282,380-4,466-474.251,535
Other Financing Activities
-0-0-0--8.94-0
Financing Cash Flow
-2,6761,3282,380-4,466-483.191,535

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
186.7338.05138.15-91.7-198.351.74
Miscellaneous Cash Flow Adjustments
-0-----
Net Cash Flow
6,4612,408966.43-5,155-2,092-1,237

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
8,9281,025-5,2373,372-1,311-2,831
Free Cash Flow Growth
------
Free Cash Flow Margin
17.48%1.97%-9.78%6.43%-2.62%-7.00%
Free Cash Flow Per Share
-87.87-449.20289.20-146.00-332.16
Levered Free Cash Flow
6,821-5.64-7,405-524.76-2,4591,277
Unlevered Free Cash Flow
7,182355.16-7,129-248.19-1,7571,984

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
591.5570.07427.49442.51491.88457.9
Cash Income Tax Paid
204.01188.6811.534.3631.28165.54
Change in Working Capital
5,216-2,500-8,663-2,389-5,506364.94